FMP
Defiance Nasdaq Junior Biotechnology ETF
IBBJ
NASDAQ
Inactive Equity
The investment seeks to track the total return performance, before fees and expenses, of the NASDAQ Junior Biotechnology Index. The index is a rules-based index that consists of a portfolio of the stock of U.S.-listed small capitalization ("junior") companies screened from the universe of the NASDAQ Biotechnology Index. The fund will generally use a "replication" strategy to achieve its investment objective, meaning it will generally invest in all of the component securities of the index in the same approximate proportions as in the index. The fund is non-diversified.
29.87 USD
-0.02 (-0.06696%)
N/A
N/A
N/A
N/A
NASDAQ
The investment seeks to track the total return performance, before fees and expenses, of the NASDAQ Junior Biotechnology Index. The index is a rules-based index that consists of a portfolio of the stock of U.S.-listed small capitalization ("junior") companies screened from the universe of the NASDAQ Biotechnology Index. The fund will generally use a "replication" strategy to achieve its investment objective, meaning it will generally invest in all of the component securities of the index in the same approximate proportions as in the index. The fund is non-diversified.
0001540305
US26922A1491
N/A
N/A
833-333-9383
US
N/A
Aug 3, 2020
US26922A1491
NASDAQ
0
8.23M
27.85-41.45
2.45k
29.87
US
-
-
-
-
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.